Heyu-B(02256): "The Lancet"(The Lancet) releases Betjemax® Global Phase III MANEUVER Study Results

LootboxPhobia · 2026-03-09T02:08:59+00:00

HeYu-B's subsidiary announced the results of a Phase III study of the new oral small-molecule CSF-1R inhibitor BejeMai®; the findings have been published in The Lancet, marking a significant advancement in its clinical research and international recognition.

LootboxPhobia

2026-03-09 02:08:59

Abstract generation in progress

Tongtong Finance APP News, HeYu-B (02256) announced that its subsidiary, Shanghai HeYu Biopharmaceutical Technology Co., Ltd. (HeYu Pharmaceuticals), announced that its independently developed new oral, highly selective, and efficient small molecule CSF-1R inhibitor Bejimai® (Pimoditin hydrochloride capsules, ABSK021) has its global multicenter Phase III MANEUVER study results officially published in the international medical journal The Lancet on March 5 (Western European time). This publication marks an important milestone for HeYu Pharmaceuticals’ innovative therapy in terms of clinical research quality, data integrity, and international academic recognition.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.